MedTrace Logo

Restart TICrH AP Pilot Trial

NCT05000060 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-10-07

No results posted yet for this study

Summary

A Prospective Randomized Open-Label Blinded Endpoint (PROBE) Pilot Trial of restarting antiplatelet therapy at 1 week versus 3 weeks after traumatic intracranial hemorrhage with a primary composite endpoint of major bleeding and vascular occlusive events.

Conditions

  • Traumatic Intracranial Hemorrhage

Interventions

OTHER

Timing/1 week

Time of restart of antiplatelet therapy is one week after injury

OTHER

Timing/3 weeks

Time of restart of antiplatelet therapy is left to treating clinician discretion

Sponsors & Collaborators

  • University of Texas at Austin

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-10-01
Completion
2023-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05000060 on ClinicalTrials.gov